Key Developments In 2008 For China Pharmaceutical Agents
This article was originally published in PharmAsia News
With the imminent rollout of China's various medical regulatory policies, drug agents are in for tougher times this year. China Pharmaceutical News has identified several major trends in the industry. 1) Mature brands will comprise the mainstay for local agents in 2008 as the entry barrier is much lower than that for newer drugs. Foreign agents dominate new products due to their market development strengths. 2) With intensifying competition, branded products will become agents' choice as savvy consumers increasingly opt for brand names that promise safety and reliability. 3) Agents are switching from single-product to multiproduct strategy to meet rising operating costs. Selling more products to an existing customer base can grow profit with minimal investment. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.